이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Traws Pharma 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Werner Cautreels

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

CEO

Werner Cautreels (72 yo)

less than a year

테뉴어

Dr. Werner Cautreels, Ph.D. serves as Member of Advisory Board at Thuja Capital Management B.V. He also serves as Chief Executive Officer & Director of Traws Pharma, Inc. since April 01, 2024. He has been...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mark Guerin	Chief Financial Officer	8.6yrs	US$745.52k	0.086% $ 8.1k
Victor Moyo	Chief Medical Officer of Oncology	1.1yrs	US$405.25k	데이터 없음
Iain Dukes	Executive Chairman	less than a year	데이터 없음	0.15% $ 13.7k
Werner Cautreels	CEO & Director	less than a year	데이터 없음	데이터 없음
Nikolay Savchuk	COO & Director	less than a year	데이터 없음	2.09% $ 195.4k
Robert Redfield	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Charles Pauza	Chief Scientific Officer of Virology	less than a year	데이터 없음	데이터 없음

0.4yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 0T2 의 관리팀은 경험 (평균 재직 기간 0.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Iain Dukes	Executive Chairman	less than a year	데이터 없음	0.15% $ 13.7k
Werner Cautreels	CEO & Director	less than a year	데이터 없음	데이터 없음
Nikolay Savchuk	COO & Director	less than a year	데이터 없음	2.09% $ 195.4k
Jack Stover	Independent Director	8.3yrs	US$126.72k	0.00044% $ 41.2
Alan Williamson	Chairman of Scientific Advisory Board	7.8yrs	데이터 없음	데이터 없음
Stephen Nimer	Member of Scientific Advisory Board	19.5yrs	데이터 없음	데이터 없음
David Parkinson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ross Donehower	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
George Vande Woude	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Anna Skalka	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Mary Shoemaker	Independent Director	4.3yrs	US$118.22k	0.0074% $ 692.4
Trafford Clarke	Independent Director	1.8yrs	US$104.22k	0% $ 0

3.0yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: 0T2 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.

Traws Pharma 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Traws Pharma, Inc. Announces Board Changes

High number of new directors

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Recent updates

Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma, Inc. Announces Board Changes

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024

New minor risk - Shareholder dilution

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2023)

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Traws Pharma, Inc. Announces Chief Executive Office Changes

Traws Pharma, Inc. Announces Board Changes

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

Full year 2023 earnings released: US$0.90 loss per share (vs US$0.91 loss in FY 2022)

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

New major risk - Share price stability

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Third quarter 2023 earnings released: US$0.23 loss per share (vs US$0.26 loss in 3Q 2022)

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.19 loss in 2Q 2022)

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.20 loss in 1Q 2022)

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: US$0.91 loss per share (vs US$0.96 loss in FY 2021)

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors

Onconova Therapeutics, Inc. Announces Board Appointments

Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.22 loss in 3Q 2021)

Onconova Therapeutics, Inc. Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Onconova Therapeutics, Inc. Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

Second quarter 2022 earnings released: EPS: US$0 (vs US$0.27 loss in 2Q 2021)

Onconova Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Onconova Therapeutics, Inc., Annual General Meeting, Aug 18, 2022

Onconova Therapeutics, Inc. Announces Executive Changes

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.32 loss in 1Q 2021)

Onconova Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma

Onconova Therapeutics, Inc. Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces the Publication of a Preclinical Study in the Journal Molecular Cancer

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

Onconova Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 11, 2021

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces Resignation of Richard C. Woodman, MD, Senior Vice President Chief Medical Officer

Onconova Therapeutics, Inc. Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300

Manoj Maniar, Ph.D., Senior Vice President, Product Development departs from Onconova Therapeutics, Inc

Onconova Therapeutics Files Investigational New Drug Application for Multi-Kinase CDK4/6 Inhibitor ON 123300

Onconova Therapeutics, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals

Onconova Therapeutics, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Onconova Therapeutics Announces Compliance with Nasdaq Bid Price Requirement

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령